login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ROYALTY PHARMA PLC- CL A (RPRX) Stock News
USA
- NASDAQ:RPRX -
GB00BMVP7Y09
-
Common Stock
38.96
USD
+0.42 (+1.09%)
Last: 11/11/2025, 8:00:01 PM
38.96
USD
0 (0%)
After Hours:
11/11/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RPRX Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Chartmill
Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance
11 days ago - By: Chartmill
ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup
7 days ago - By: Benzinga
- Mentions:
QCOM
ZBH
DVN
TOST
...
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?
7 days ago - By: Zacks Investment Research
Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
7 days ago - By: Zacks Investment Research
- Mentions:
MRSN
Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates
7 days ago - By: Royalty Pharma plc
Royalty Pharma Reports Third Quarter 2025 Results
7 days ago - By: Royalty Pharma plc
Royalty Pharma Reports Third Quarter 2025 Results
7 days ago - By: Benzinga
- Mentions:
TECH
INSE
GEF
SKYT
...
Earnings Scheduled For November 5, 2025
8 days ago - By: Royalty Pharma plc
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
8 days ago - By: Royalty Pharma plc
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
14 days ago - By: Zacks Investment Research
- Mentions:
RYTM
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
26 days ago - By: Royalty Pharma plc
Royalty Pharma Declares Fourth Quarter 2025 Dividend
26 days ago - By: Royalty Pharma plc
Royalty Pharma Declares Fourth Quarter 2025 Dividend
a month ago - By: Royalty Pharma plc
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
a month ago - By: Royalty Pharma plc
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
a month ago - By: Royalty Pharma plc
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
a month ago - By: Royalty Pharma plc
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
2 months ago - By: Royalty Pharma plc
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
2 months ago - By: Royalty Pharma plc
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
2 months ago - By: Yahoo Finance
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
2 months ago - By: Royalty Pharma plc
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
2 months ago - By: Royalty Pharma plc
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
2 months ago - By: Royalty Pharma plc
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
2 months ago - By: Royalty Pharma plc
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
2 months ago - By: Royalty Pharma plc
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
2 months ago - By: Royalty Pharma plc
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
2 months ago - By: Royalty Pharma plc
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
2 months ago - By: Royalty Pharma plc
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
2 months ago - By: Royalty Pharma plc
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
2 months ago - By: Royalty Pharma plc
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
Please enable JavaScript to continue using this application.